Oncology

Progression free survival and overall response rate were higher in patients with R/R MM treated with Abecma than those treated with standard of care.

Review top news and interview highlights from the week ending February 10, 2023.

The updated data included a median overall survival of 26 months after treatment with brexu-cel.

The latest data set includes 22 newly evaluable patients with triple-refractory disease.

The POLARIS study adds to the growing body of evidence validating GPRC5D as a target for CAR T-cell therapy in R/R MM.

A focused discussion on clinical trial data presented at SITC 2022 elucidating the biologic activity of tumor-infiltrating lymphocyte therapies.

Amod Sarnaik, MD, and Krishna Komanduri, MD, share their clinical experience with, and practical advice on, tumor-infiltrating lymphocyte therapy for their patients with solid tumors.

The FDA cleared Century’s IND for CNTY-101 in August 2022.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The associate professor of medicine from University of Pennsylvania discussed advantages of huCART19-IL18 in NHL and CLL.

Patients treated with ALLO-715 achieved an ORR of 55.8%.

The associate attending physician at Memorial Sloan Kettering Cancer Center discussed further research that remains to be conducted with the allogeneic cell therapy.

GC012F recently showed efficacy in newly-diagnosed MM in investigator-initiated trials.

The assistant member of the department of malignant hematology at Moffitt Cancer Center discussed updated data on the allogeneic CAR T therapy, UNICART123v1.2.

Review top news and interview highlights from the week ending February 3, 2023.

Shared insight on the benefits and drawbacks of using tumor-infiltrating lymphocyte therapy for treatment of solid tumors, as compared to chimeric antigen receptor (CAR) T-cell therapy.

Expert perspectives on the mechanism of action behind tumor-infiltrating lymphocyte (TIL) therapy and how it might address unmet needs in the treatment of solid tumors, including melanoma and non–small cell lung cancer.

The professor at University Hospital Dresden discussed the positive safety profile of Unicar-T-CD123.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Mesoblast is resubmitting its BLA with new CMC, survival, and mechanism of action data on the therapy and phase 3 trial.

AB-101 is also being investigated with the innate cell engager AFM13 for CD30 lymphomas.

Positive preclinical data related to SENTI-202 and SENTI-401 were presented at conferences last year.

There were no deaths or safety signals identified by the DSMB for the 3 treated patients in cohort 1.

Sana Biotechnology also plans to submit another IND for the same indications for a CD22-targeted CAR T later in 2022.

The phase 1 portion of the trial assessing CNA3103 will start enrollment in Australia in the first half of 2023; the phase 2 portion will expand to the US.